FormFactor: Compelling Entry After Investor Day Selloff

FormFactor fell 12.8% after outlining a 2030 plan for $1.6B revenue, 55% gross margin, and $5.00 non-GAAP EPS, but investors focused on execution risk rather than the long-term targets. The thesis depends on HBM4 share gains, GPU and co-packaged optics demand, and Texas plant expansion to unlock probe-card capacity. Valuation remains elevated at 12.06x forward sales, with any miss at the Texas ramp potentially pressuring 2027 guidance.

Analysis

The market is signaling that FORM’s problem is not the long-term opportunity set, but the credibility of the path to get there. A 2030 framework with a step-change in margin and EPS is only useful if investors can underwrite the bridge from here to 2027, and that bridge now carries a higher execution discount after the selloff. In semicap, the multiple usually compresses first when management turns aspirational before proving capacity and mix; the stock is effectively telling us that investors want nearer-term booking evidence, not a distant model.

Second-order, the biggest winner may be the ecosystem around advanced packaging rather than FORM itself. If HBM4 and co-packaged optics adoption stays on schedule, probe-card demand should broaden, but the incremental economics may accrue disproportionately to larger, better-capitalized suppliers with deeper customer entrenchment and faster qualification cycles. Texas capacity is the swing factor: if readiness slips, customers will pre-allocate spend to competitors, and that lost socket share can persist beyond the initial delay because test flows are sticky once designed in.

The risk window is asymmetric: the next 1-2 quarters matter more than the 2030 target. A single earnings miss or capex delay could reset 2027 guideposts and force the market to underwrite a lower growth/margin trajectory, while a clean execution update could trigger a sharp relief bounce given how stretched the valuation is relative to hardware peers. The contrarian view is that the stock may already be pricing in too much operational slippage; if Texas comes online on time and GPU/HBM4 demand inflects, the post-earnings drawdown could look like a de-rating overreaction rather than a fundamental break.

For now, the tape favors waiting for proof rather than paying up for optionality. The most attractive setup is a staged approach: short-term bearish on execution, but willing to flip if management can convert the plan into visible capacity and margin progression by the next two reporting cycles.

Key Decisions for Investors

• Stay underweight/short FORM into the next earnings window; use strength to build on any move back toward the pre-drop valuation band, targeting a 10-15% downside extension if guideposts disappoint.
• For event-driven exposure, buy FORM put spreads dated through the next 1-2 quarters; the trade benefits if the market starts to price a 2027 guide reset, while limiting premium if the stock stabilizes.
• Pair trade: short FORM / long a higher-quality semicap or advanced-packaging beneficiary with more visible execution and customer diversification; this isolates project-execution risk from the secular AI/test demand theme.
• If management confirms Texas readiness and orders improve, cover shorts quickly and consider a tactical long on a 15-20% drawdown from current levels; the stock can re-rate fast on credibility recovery.
• Avoid chasing the 2030 narrative until there is at least one quarter of evidence that capacity expansion is converting into revenue and margin flow-through; the risk/reward is unfavorable before proof.